title: Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD.
abstract: BACKGROUND
  Animal data indicate that chronic exposure to dopaminergic drugs can alter levels of the dopamine transporter (DAT), which is critically involved in regulation of synaptic dopamine levels. DAT changes could influence the response to therapy in PD.
  
  
  METHODS
  A randomized, assessor-blinded, placebo-controlled clinical trial was performed in subjects with early PD to determine whether L-dopa or pramipexole might regulate striatal DAT binding as measured by PET with [(11)C]RTI-32. Thirty clinically asymmetrical patients were randomly assigned to receive 6 weeks of L-dopa (300/75 mg/d), pramipexole (1.5 mg/d), or placebo; PET studies were performed before and after treatment.
  
  
  RESULTS
  Mean interval change in DAT binding was significantly reduced by 16% to 22% in all striatal regions (caudate, anterior and posterior putamen) of the L-dopa-treated patients, whereas significant changes in the pramipexole-treated patients were limited to the contralateral caudate (-15%), ipsilateral anterior putamen (-14%), and posterior putamen (-20%). In the placebo group there were significant changes in contralateral caudate (-11%) and ipsilateral anterior putamen (-12%). L-dopa and pramipexole produced similar clinical benefit.
  
  
  CONCLUSIONS
  Short-term therapy with L-dopa and, to a lesser extent, pramipexole can modestly down-regulate striatal DAT in patients with early PD. Decreased striatal DAT could increase dopaminergic neurotransmission with potential benefit, but might also play a role in the development of dopamine-related response fluctuations in patients with advanced disease. Our data also suggest caution in interpretation of longitudinal imaging studies employing DAT to assess disease progression and the efficacy of neuroprotective agents.
authors.affiliation: Centre for Addiction and Mental Health, Division of Neurology, Department of Psychiatry, University of Toronto, Ontario, Canada. mguttman@idirect.com
authors.forename: M
authors.initials: M
authors.lastname: Guttman
authors.forename: D
authors.initials: D
authors.lastname: Stewart
authors.forename: D
authors.initials: D
authors.lastname: Hussey
authors.forename: A
authors.initials: A
authors.lastname: Wilson
authors.forename: S
authors.initials: S
authors.lastname: Houle
authors.forename: S
authors.initials: S
authors.lastname: Kish
mesh_terms: D000368:Aged; D000978:Antiparkinson Agents / Q000008:administration & dosage*; D052160:Benzothiazoles; D001923:Brain Chemistry / Q000187:drug effects; D002250:Carbon Radioisotopes; D002352:Carrier Proteins / Q000378:metabolism*; D003042:Cocaine / Q000031:analogs & derivatives; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism; D050483:Dopamine Plasma Membrane Transport Proteins; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage*; D008297:Male; D008562:Membrane Glycoproteins; D026901:Membrane Transport Proteins; D008875:Middle Aged; D009419:Nerve Tissue Proteins; D010300:Parkinson Disease / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000378:metabolism; D000077487:Pramipexole; D011954:Receptors, Dopamine / Q000378:metabolism; D013844:Thiazoles / Q000008:administration & dosage*; D014055:Tomography, Emission-Computed
chemical_list: D000978:Antiparkinson Agents; D052160:Benzothiazoles; D002250:Carbon Radioisotopes; D002352:Carrier Proteins; D050483:Dopamine Plasma Membrane Transport Proteins; D008562:Membrane Glycoproteins; D026901:Membrane Transport Proteins; D009419:Nerve Tissue Proteins; D011954:Receptors, Dopamine; C493214:SLC6A3 protein, human; D013844:Thiazoles; C067730:RTI-COC 32; D007980:Levodopa; D000077487:Pramipexole; D003042:Cocaine